Novartis loses CHF 24bn market value after two research setbacks

Novartis shares plunged on the Swiss exchange, erasing roughly CHF 24 billion in market capitalization, following two major research failures. The setbacks likely involve late-stage trial discontinuations or regulatory rejections, though specific details are not provided. This is a significant single-stock event with potential sector-wide implications for biopharma sentiment.